Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Treace Medical Concepts Inc (TMCI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TMCI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.5% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 510.34M USD | Price to earnings Ratio - | 1Y Target Price 11.29 |
Price to earnings Ratio - | 1Y Target Price 11.29 | ||
Volume (30-day avg) 408761 | Beta 0.78 | 52 Weeks Range 3.92 - 12.74 | Updated Date 04/2/2025 |
52 Weeks Range 3.92 - 12.74 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.63% | Operating Margin (TTM) -0.22% |
Management Effectiveness
Return on Assets (TTM) -14.83% | Return on Equity (TTM) -44.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 504318608 | Price to Sales(TTM) 2.44 |
Enterprise Value 504318608 | Price to Sales(TTM) 2.44 | ||
Enterprise Value to Revenue 2.41 | Enterprise Value to EBITDA -40.95 | Shares Outstanding 62618700 | Shares Floating 47365889 |
Shares Outstanding 62618700 | Shares Floating 47365889 | ||
Percent Insiders 26.04 | Percent Institutions 60.57 |
Analyst Ratings
Rating 3.29 | Target Price 9.05 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Treace Medical Concepts Inc
Company Overview
History and Background
Treace Medical Concepts, Inc. was founded in 2014 and is headquartered in Ponte Vedra Beach, Florida. The company focuses on developing and commercializing innovative solutions for bunion surgery.
Core Business Areas
- Bunion Correction: Treace develops and commercializes the Lapiplastyu00ae System, a 3D bunion correction procedure using patented instruments and implants to correct all three dimensions of the bunion deformity.
Leadership and Structure
John T. Treace is the CEO and Founder. The company has a standard corporate structure with departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Lapiplastyu00ae System: This system addresses all three dimensions of a bunion deformity. While specific market share data is variable and changes over time, Treace is a leader in the 3D bunion correction market. Key competitors include Stryker (SYK), Wright Medical (now part of Stryker) for traditional bunionectomy procedures, and other companies developing minimally invasive bunion correction techniques.
Market Dynamics
Industry Overview
The foot and ankle market is growing due to an aging population, increasing prevalence of foot conditions, and advancements in surgical techniques and technologies. This includes bunion correction procedures.
Positioning
Treace is positioned as an innovator in the bunion correction market with its Lapiplastyu00ae System, offering a differentiated approach compared to traditional bunionectomy procedures. Their competitive advantage lies in addressing all three dimensions of the deformity.
Total Addressable Market (TAM)
The total addressable market for bunion correction is estimated to be billions of dollars annually. Treace is positioned to capture a significant portion of this market with its Lapiplastyu00ae System, penetrating the market as the preference for 3D correction continues to grow.
Upturn SWOT Analysis
Strengths
- Innovative Lapiplastyu00ae System
- Strong IP portfolio
- Growing market adoption
- Dedicated sales force
Weaknesses
- Relatively small company size
- Dependence on Lapiplastyu00ae System
- Limited product diversification
- Higher procedure cost compared to traditional bunionectomies
Opportunities
- Expanding market reach
- Developing new applications for Lapiplastyu00ae System
- Acquiring complementary technologies
- Increasing patient awareness and education
Threats
- Competition from established orthopedic companies
- Pricing pressure
- Reimbursement challenges
- Potential product liability claims
Competitors and Market Share
Key Competitors
- SYK
- BSX
- JNJ
Competitive Landscape
Treace Medical Concepts has the advantage of offering a novel surgical technique, but struggles with scale and resources when compared to larger firms. Stryker and Boston Scientific have a diverse portfolio of products, allowing them to weather the ups and downs of any single market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Treace has experienced significant revenue growth driven by increased adoption of the Lapiplastyu00ae System.
Future Projections: Analyst projections vary, but generally forecast continued revenue growth driven by market penetration and expansion.
Recent Initiatives: Recent initiatives include expanding sales force, launching new products related to the Lapiplastyu00ae System, and increasing marketing efforts.
Summary
Treace Medical Concepts is a growing company with an innovative product in the bunion correction market. The company's Lapiplasty system has gained traction, driving revenue growth. However, the company is relatively small and dependent on a single product. It faces competition from larger, more established orthopedic companies. The company should continue to expand its market reach and develop new applications for its technology to drive long-term growth.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Treace Medical Concepts Inc
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2021-04-23 | CEO, Founder & Director Mr. John T. Treace | ||
Sector Healthcare | Industry Medical Devices | Full time employees 477 | Website https://www.treace.com |
Full time employees 477 | Website https://www.treace.com | ||
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.